MedPath

NEUROCRINE BIOSCIENCES, INC.

NEUROCRINE BIOSCIENCES, INC. logo
🇸🇪Sweden
Ownership
Public
Established
1992-01-01
Employees
1.4K
Market Cap
$15.4B
Website
http://www.neurocrine.com
pharmaphorum.com
·

BMS ends decades-long drought in novel schizophrenia drugs

Bristol-Myers Squibb 's $14 billion acquisition of Karuna Therapeutics pays off with FDA approval for Cobenfy , a novel schizophrenia drug targeting cholinergic receptors. Cobenfy offers a new treatment approach with milder side effects compared to dopamine-blocking drugs, potentially leading to blockbuster sales. BMS plans to launch Cobenfy at $1,850 per month, with further clinical trials underway for additional indications.

Top 10 FA News Stories of 2024

Friedreich’s Ataxia News highlighted 2024's top FA research and treatments, including vatiquinone 's FDA approval pursuit, gene therapy advancements, and novel treatments like DT-216P2 and PPL-001 . Studies showed improvements in FA symptoms, mitochondrial function, and heart defects in mice, aiming for better FA management.
biochempeg.com
·

2024 FDA Approvals: 50 New Drugs

In 2024, FDA's CDER approved 50 new drugs, including 32 NCEs and 18 NBEs, with small molecules and antibody-based drugs dominating. First-in-class drugs accounted for 44% of approvals, with notable approvals like Rezdiffra for NASH and Voranigo for brain tumors. Nucleic acid and peptide-based drugs made up 10% of approvals, including Rytelo for MDS. FDA also approved 8 cell and gene therapies, marking a record and introducing first treatments for several diseases.
pharmaphorum.com
·

SOM's AI-discovered drug shows promise in Huntington's disease

SOM3355, a drug initially for hypertension, shows promise in treating Huntington's disease by reducing chorea symptoms. A phase 2 trial demonstrated its effectiveness with minimal side effects. Developed via AI, it may offer a safer alternative to existing treatments, with potential peak sales of €1.1 billion.
hcplive.com
·

Endocrinology Month in Review: December 2024

December 2024 saw significant endocrinology updates: tirzepatide outperformed semaglutide in weight loss, mifepristone reduced HbA1c in T2D, FDA approved crinecerfont for CAH and a generic GLP-1 RA for T2D. Diabetes Dialogue podcast highlighted diabetes tech and therapy advancements.
hcplive.com
·

FDA News Month in Review: December 2024

December 2024 FDA updates: Approved treatments include ustekinumab-kfce for inflammatory diseases, crinecerfont for CAH, nemolizumab for AD, and olezarsen for FCS. Notable actions: RMAT designation for rexlemestrocel-L , Boxed Warning for fezolinetant , and CRLs for glepaglutide and sotagliflozin . Pipeline updates: Tirzepatide outperformed semaglutide in weight loss, and novel therapies for HCV, PNH, and EoE showed promise.
hdbuzz.net
·

2024: Year in Review - Huntington's disease research news

2024 marked significant progress in Huntington’s disease (HD) research, with breakthroughs in understanding somatic instability, advancements in drug development, and both challenges and triumphs in clinical trials. The HD community saw the power of collaboration and innovation, with new voices at HDBuzz and updates from global conferences. Despite setbacks, there's hope with ongoing trials and new drug approvals, moving closer to treatments that could slow or halt HD.
medcitynews.com
·

FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions

The FDA made significant regulatory decisions, including the first drug approval for obstructive sleep apnea, a novel regenerative medicine for trauma patients, and treatments for rare diseases and cancer. Notable approvals include Eli Lilly ’s Zepbound , Ionis Pharmaceuticals Tryngolza , and Humacyte ’s Symvess . The FDA also expanded uses for existing drugs and issued rejections and warnings for others.

FDA grants approval of Crenessity (crinecerfont), a first-in-class treatment for classic congenital adrenal hyperplasia

Neurocrine Biosciences' Crenessity (crinecerfont) received FDA approval for treating classic congenital adrenal hyperplasia (CAH) in patients aged 4 and older. It's the first treatment to directly reduce excess ACTH and adrenal androgen production, enabling glucocorticoid dose reduction. Supported by the largest CAH clinical trials, Crenessity showed efficacy in lowering steroid doses and androgen levels with few adverse effects.
© Copyright 2025. All Rights Reserved by MedPath